GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Exploring Collateral Lethality for Development of Cancer Therapeutics

$474,054
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA

Exploring Collateral Lethality for Development of Cancer Therapeutics

$474,053
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · CA

Exploring Collateral Lethality for Development of Cancer Therapeutics

$474,053
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA

Project 3: Transcriptomic subtypes, response predictions, and therapy selection

$473,937
Jen Jen Yeh · Univ Of North Carolina Chapel Hill · P50 · FY2025 · CA

A novel miR-198 replacement therapy for pancreatic cancer

$473,915
Qizhi C. Yao · Baylor College Of Medicine · R01 · FY2017 · CA

A novel miR-198 replacement therapy for pancreatic cancer

$473,915
Qizhi C. Yao · Baylor College Of Medicine · R01 · FY2016 · CA

A novel miR-198 replacement therapy for pancreatic cancer

$473,915
Qizhi C. Yao · Baylor College Of Medicine · R01 · FY2018 · CA

Cyst-X: Interpretable Deep Learning Based Risk Stratification of Pancreatic Cystic Tumors

$473,759
Ulas Bagci · Northwestern University At Chicago · R01 · FY2024 · CA

Transcriptional Regulators of the Exocrine Pancreatic Phenotype

$473,738
Raymond J. Macdonald · Ut Southwestern Medical Center · R01 · FY2017 · DK

Indiana University (IU) Clinical Center for Chronic Pancreatitis Clinical Research Network

$473,661
Evan L Fogel · Indiana University Indianapolis · U01 · FY2020 · DK

Rational in situ programming of cancer vaccine-responding T-cell clones

$473,651
Matthias Stephan · Fred Hutchinson Cancer Center · R01 · FY2025 · CA

Role of micro-RNAs in T cells and other immune/haematopoietic cells

$473,500
Anjana Rao · Immune Disease Institute, Inc. · R01 · FY2007 · AI

Target discovery and combination therapy in KRAS mutant cancer

$473,481
Ji Luo · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Thrombin-dependent mechanisms of pancreatic ductal adenocarcinoma disease

$473,443
Matthew J. Flick · Univ Of North Carolina Chapel Hill · R01 · FY2019 · CA

Biomolecular Recognition and Binding Mechanisms

$473,373
Ruth Nussinov · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Glucocorticoids in Lymphoblastic Leukemia

$473,354
Mary V. Relling · St. Jude Children'S Research Hospital · R01 · FY2019 · CA

Biology and Immunology of Pancreatic Cancer Stem Cells in a Novel Mouse Model

$473,351
Edgar G. Engleman · Stanford University · U01 · FY2012 · CA

Machine learning accelerated on-line adaptive replanning

$473,295
Eric S Paulson · Medical College Of Wisconsin · R01 · FY2023 · CA

Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer

$473,270
Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2022 · CA

Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma

$473,270
Ethan Vincent Abel · Roswell Park Cancer Institute Corp · R37 · FY2023 · CA

Transcriptional Regulators of the Exocrine Pancreatic Phenotype

$473,186
Raymond J. Macdonald · Ut Southwestern Medical Center · R01 · FY2016 · DK

Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW v-49

$473,179
William G Hawkins · Washington University · P50 · FY2020 · CA

Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer

$473,142
Pankaj Kumar Singh · University Of Nebraska Medical Center · R01 · FY2020 · CA

Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer

$473,142
Pankaj Kumar Singh · University Of Nebraska Medical Center · R01 · FY2021 · CA

Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer

$473,142
Pankaj Kumar Singh · University Of Nebraska Medical Center · R01 · FY2019 · CA